This summary was created by AI, based on 6 opinions in the last 12 months.
Experts are generally positive about Regeneron Pharmaceuticals Inc (REGN-Q) despite recent market cap losses and bad news. They view it as a buying opportunity with a strong CEO and a promising drug pipeline, particularly in the obesity and weight-loss market. The company's focus on organic growth and development of its drugs in-house or with partners has also been highlighted, along with its successful protection of patents and introduction of new drug versions. Despite its growth, REGN trades at a low forward PE and has announced a share buyback. Analysts expect significant long-term potential and see no major obstacles in its trajectory.
Run by a fine CEO. Shares are up long term, and they have a lot of promising drugs in their pipeline, including one in weight-loss.
It's had bad news this week, but it rarely gets a pull back. Long term this is fine.
Are showcasing their key drugs next week, but he remains focused on their obesity drug candidate. It's still early in those test results.
He's bullish pharmas if the economy weakens. He likes it for growing organically, not buying companies, and in developing its drugs in-house or with partners. Their drug pipeline overcomes worries of their existing drugs coming off patent. Their key drug, Eylea, topped $1.04 billion in Q1 and $5.89 billion in full-year US net sales. But Roche has released a rival drug, while Eylea will come off patent in a couple years as they successfully protect their patent in court. Also, REGN just developed a new version of Eylea. Dupixent is their second-biggest drug and is performing well as well. Despite its growth, REGN trades at only 22x forward PE, and announced a $3 billion share buyback.
An analyst upgraded this to $1,025, a very long way to go. He's gained 40% in this himself. It's reasonable at a 24x PE and enjoys momentum. Sees nothing to derail this.
The momentum is waning, and last quarter revenue growth was only 14%. They're coming to the end of the road.
Shares are down in the past 24 hours due to a delay in a drug approval. But another drug remains strong in sales, and they have double-digit in oncology drugs in trials. A great science company.
A quality company. Trades at 17x. The FDA is delaying approval of a drug, but that is correctable because the issue isn't about safety or efficacy.
Trades at 19x earnings, but have a huge drug pipeline.
Regeneron Pharmaceuticals Inc is a American stock, trading under the symbol REGN-Q on the NASDAQ (REGN). It is usually referred to as NASDAQ:REGN or REGN-Q
In the last year, 6 stock analysts published opinions about REGN-Q. 5 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Regeneron Pharmaceuticals Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
6 stock analysts on Stockchase covered Regeneron Pharmaceuticals Inc In the last year. It is a trending stock that is worth watching.
On 2024-12-11, Regeneron Pharmaceuticals Inc (REGN-Q) stock closed at a price of $773.
It's lost a third of its market cap and the selling is overdone. Now, is a buying opportunity.